Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Target Price
The average target price of KZR is 6.3 and suggests 15% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Buy
Sell